These results support further investigation into the inclusion of a FAK TKI to treatment with EGFR TKIs such as erlotinib, particularly in NSCLC with wild-type EGFR and inherent erlotinib resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.